Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.

Kumar N, Zhao D, Bhaumik D, Sethi A, Gann PH.

BMC Cancer. 2019 Mar 8;19(1):215. doi: 10.1186/s12885-019-5392-z.

2.

Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes.

Caan BJ, Sweeney C, Habel LA, Kwan ML, Kroenke CH, Weltzien EK, Quesenberry CP Jr, Castillo A, Factor RE, Kushi LH, Bernard PS.

Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):725-34. doi: 10.1158/1055-9965.EPI-13-1017. Epub 2014 Feb 12.

3.

Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.

Laurberg T, Alsner J, Tramm T, Jensen V, Lyngholm CD, Christiansen PM, Overgaard J.

Acta Oncol. 2017 Jan;56(1):59-67. doi: 10.1080/0284186X.2016.1246803. Epub 2016 Nov 16.

PMID:
27846764
4.

Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.

Sweeney C, Bernard PS, Factor RE, Kwan ML, Habel LA, Quesenberry CP Jr, Shakespear K, Weltzien EK, Stijleman IJ, Davis CA, Ebbert MT, Castillo A, Kushi LH, Caan BJ.

Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):714-24. doi: 10.1158/1055-9965.EPI-13-1023. Epub 2014 Feb 12.

5.

Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.

Prat A, Brase JC, Cheng Y, Nuciforo P, Paré L, Pascual T, Martínez D, Galván P, Vidal M, Adamo B, Hortobagyi GN, Baselga J, Ciruelos E.

Oncologist. 2019 Jan 24. pii: theoncologist.2018-0407. doi: 10.1634/theoncologist.2018-0407. [Epub ahead of print]

PMID:
30679318
6.

Prediction consistency and clinical presentations of breast cancer molecular subtypes for Han Chinese population.

Huang CC, Tu SH, Lien HH, Jeng JY, Liu JS, Huang CS, Wu YY, Liu CY, Lai LC, Chuang EY.

J Transl Med. 2012 Sep 19;10 Suppl 1:S10. doi: 10.1186/1479-5876-10-S1-S10. Epub 2012 Sep 19.

7.

Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.

Kelly CM, Bernard PS, Krishnamurthy S, Wang B, Ebbert MT, Bastien RR, Boucher KM, Young E, Iwamoto T, Pusztai L.

Oncologist. 2012;17(4):492-8. doi: 10.1634/theoncologist.2012-0007. Epub 2012 Mar 14.

8.

Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.

Kim HK, Park KH, Kim Y, Park SE, Lee HS, Lim SW, Cho JH, Kim JY, Lee JE, Ahn JS, Im YH, Yu JH, Park YH.

Cancer Res Treat. 2019 Apr;51(2):737-747. doi: 10.4143/crt.2018.342. Epub 2018 Sep 5.

9.

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Seguí MÁ, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Antón A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martín M.

BMC Med Genomics. 2012 Oct 4;5:44. doi: 10.1186/1755-8794-5-44.

10.

Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.

Sánchez-Muñoz A, Vicioso L, Santonja A, Álvarez M, Plata-Fernández Y, Miramón J, Zarcos I, Ramírez-Tortosa CL, Montes-Torres J, Jerez JM, de Luque V, Llácer C, Fernández-De Sousa CE, Pérez-Villa L, Alba E.

Mod Pathol. 2018 Feb;31(2):299-306. doi: 10.1038/modpathol.2017.129. Epub 2017 Oct 6.

11.

PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study Cohorts.

Kensler KH, Sankar VN, Wang J, Zhang X, Rubadue CA, Baker GM, Parker JS, Hoadley KA, Stancu AL, Pyle ME, Collins LC, Hunter DJ, Eliassen AH, Hankinson SE, Tamimi RM, Heng YJ.

Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):798-806. doi: 10.1158/1055-9965.EPI-18-0863. Epub 2018 Dec 27.

PMID:
30591591
12.

Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.

Netanely D, Avraham A, Ben-Baruch A, Evron E, Shamir R.

Breast Cancer Res. 2016 Jul 7;18(1):74. doi: 10.1186/s13058-016-0724-2. Erratum in: Breast Cancer Res. 2016 Nov 28;18(1):117.

13.

Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.

Prat A, Cheang MC, Galván P, Nuciforo P, Paré L, Adamo B, Muñoz M, Viladot M, Press MF, Gagnon R, Ellis C, Johnston S.

JAMA Oncol. 2016 Oct 1;2(10):1287-1294. doi: 10.1001/jamaoncol.2016.0922.

PMID:
27281556
14.

Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression.

Kroenke CH, Sweeney C, Kwan ML, Quesenberry CP, Weltzien EK, Habel LA, Castillo A, Bernard PS, Factor RE, Kushi LH, Caan BJ.

Breast Cancer Res Treat. 2014 Apr;144(3):689-99. doi: 10.1007/s10549-014-2899-5. Epub 2014 Mar 7.

15.

Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer.

Cespedes Feliciano EM, Kwan ML, Kushi LH, Chen WY, Weltzien EK, Castillo AL, Sweeney C, Bernard PS, Caan BJ.

Cancer. 2017 Jul 1;123(13):2535-2542. doi: 10.1002/cncr.30637. Epub 2017 Mar 13.

16.

Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression.

Kwan ML, Kroenke CH, Sweeney C, Bernard PS, Weltzien EK, Castillo A, Factor RE, Maxfield KS, Stijleman IJ, Kushi LH, Quesenberry CP Jr, Habel LA, Caan BJ.

BMC Cancer. 2015 Apr 14;15:278. doi: 10.1186/s12885-015-1263-4.

17.

Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.

Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, Kyte JA, Kristensen VN, Geitvik GA, Schlichting E, Wist EA, Sørlie T, Russnes HG, Naume B.

Breast Cancer Res. 2017 Nov 14;19(1):120. doi: 10.1186/s13058-017-0911-9.

18.

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.

Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J, Vickery T, Davies SR, Mardis ER, Gnant M, Sestak I, Ellis MJ, Perou CM, Bernard PS, Parker JS.

BMC Med Genomics. 2015 Aug 22;8:54. doi: 10.1186/s12920-015-0129-6.

19.

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.

Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA.

J Clin Oncol. 2011 Jun 10;29(17):2342-9. doi: 10.1200/JCO.2010.31.6950. Epub 2011 May 9.

20.

SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.

Abdel-Fatah TMA, Agarwal D, Liu DX, Russell R, Rueda OM, Liu K, Xu B, Moseley PM, Green AR, Pockley AG, Rees RC, Caldas C, Ellis IO, Ball GR, Chan SYT.

Lancet Oncol. 2016 Jul;17(7):1004-1018. doi: 10.1016/S1470-2045(16)00174-1. Epub 2016 Jun 14.

PMID:
27312051

Supplemental Content

Support Center